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raplB is a member of the ras superfamily of low 
molecular weight GTP binding proteins which consti- 
tutes a focal point of GTP and CAMP signal transduc- 
tion systems. Like other members of this superfamily, 
raplB is membrane-associated in resting platelets, 
presumably through polyisoprenylation. The studies 
presented here were undertaken to determine the sub- 
cellular changes in raplB localization during cell ac- 
tivation. Activated and unactivated platelets were 
fractionated by Triton X-100 lysis followed by differ- 
ential centrifugation to obtain a 10,000 X g cytoskel- 
eton fraction, a 100,000 x g membrane skeleton frac- 
tion, and a 100,000 x g supernatant fraction contain- 
ing solubilized proteins. In unactivated platelets, 
raplB was present in the 100,000 x g supernatant 
fraction. In contrast, in platelets activated with 1 unit/ 
ml a-thrombin or with the calcium ionophore, A23187, 
raplB was quantitatively recovered in the 10,000 x g 
cytoskeleton fraction. raplB was absent from the 
100,000 x g fraction containing the membrane skele- 
ton and could not be detected in the 100,000 x g 
supernatant containing cytosolic proteins and solubi- 
lized membrane components. These results indicate 
that raplB associates with the cytoskeleton during cell 
activation. 
Low molecular weight GTP-binding proteins are ubiquitous 
cellular components which function as molecular switches 
early in the signal transduction pathways for cell growth and 
differentiation (l-3). Control of this switch is through guanine 
nucleotide binding; GDP-ligated forms of these proteins are 
inactive while GTP-ligated forms are active, stimulating cell 
growth and differentiation. According to current views, fol- 
lowing an extracellular signal for activation, the inactive 
GDP-ligated protein is converted to the active GTP-ligated 
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protein through a nucleotide exchange reaction. Conversion 
back to the inactive GDP-ligated protein is facilitated by 
cytosolic proteins known as GTPase-activating proteins, 
which enhance the endogenous GTPase activity of the low 
molecular weight proteins (4). To date, more than 20 distinct 
low molecular weight G proteins’ have been identified (5). 
The prototype for these proteins is p21”, the product of the 
ras protooncogene. 
The subcellular localization of the low molecular weight G 
proteins appears to be essential for their activity. Two sites 
of membrane localization have been identified. ~21’” and its 
homologs are localized to the cytoplasmic face of the plasma 
membrane, and this localization is absolutely required for 
transforming activity (6). Localization to the plasma mem- 
brane is a complex process that involves a series of posttrans- 
lational modifications resulting in covalent attachment of a 
polyisoprenyl group, typically farnesyl, to the C-terminal cys- 
teine residue (7). The signal for polyisoprenylation is the C- 
terminal propeptide sequence, Cys-Ali-Ali-Xaa (where Ali is 
any aliphatic amino acid and Xaa is any amino acid). Follow- 
ing polyisoprenylation, the three C-terminal amino acids (Ali- 
Ali-Xaa) are proteolytically removed and the C-terminal cys- 
teine is carboxymethylated to yield the mature protein with a 
polyisoprenylated C-terminal cysteine residue. Mutations of 
the C-terminal cysteine residue block both polyisoprenylation 
and membrane localization, as well as the transforming activ- 
ity (6, 8). The localization of these proteins to the plasma 
membrane is presumed to be essential for their signal-trans- 
ducing activity. Another group of low molecular weight G 
proteins, represented by the yeast proteins Sec4 and YPTl, 
have been localized to internal membranes (9, 10). These 
proteins lack the Cys-Ali-Ali-Xaa signal required for poly- 
isoprenylation but have a C-terminal cysteine residue. It is 
not known if these proteins are polyisoprenylated or palmi- 
tylated. 
Recently, a 22-kDa substrate for CAMP-dependent protein 
kinase in human blood platelets, previously termed p22 or 
thrombolamban (ll-16), was identified as a low molecular 
weight G protein. This identification was based on evidence 
that the protein hydrolyzed GTP and was recognized by 
antibodies against the GTP-binding domain of ~21” (17-21). 
Partial protein sequence for the platelet protein (22-24)’ was 
identical with raplB (26), a member of the rus superfamily 
also known as smg-p21B (17) or m22KG(I) (18). Like p21”, 
raplB in platelets is membrane-associated (19, 21) and has a 
consensus polyisoprenylation sequence (23-24).* RaplB is 
phosphorylated in intact platelets by prostaglandin I2 or lipid 
soluble analogs of CAMP and in membrane fractions by type 
I CAMP-dependent protein kinase or the catalytic subunit of 
CAMP-dependent protein kinase (ll-16,20). The phosphoryl- 
ated amino acid was shown to be a serine (16), and the 
sequence at the phosphorylation site has been identified as 
-Arg-Lys-Lys-Ser-Ser-Cys-COOH (24).’ Phosphorylation of 
raplB in intact platelets results in translocation of the protein 
from a membrane fraction to a cytosolic fraction (19). Phos- 
’ The abbreviations used are: G protein, GTP-binding protein; 
MES, 4-morpholineethanesulfonic acid; HEPES, 4-(2-hydroxyethyl)- 
l-piperazineethanesulfonic acid; EGTA, [ethylenebis(oxyethylene- 
nitrilo)]tetraacetic acid. 
‘T. H. Fischer, J. H. Collins, M. Gatling, and G. C. White II, 
FEBS Lett., submitted for publication. 
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phorylation had no effect on the GTPase activity of raplB, 
and the phosphorylation of GTP- and GDP-bound forms of 
raplB was kinetically similar (17). 
Because of its potential importance in cell activation and 
its known membrane localization, the present study was un- 
dertaken to examine the cellular localization of raplB in 
platelets during activation and was based on several obser- 
vations. First, since raplB is membrane-associated, probably 
through either palmitylation or polyisoprenylation of the C- 
terminal cysteine residue, it was important to determine what 
happens to the protein during normal cell function. Second, 
the site of phosphorylation of raplB is remarkably close to 
the site of membrane attachment (24),” suggesting that mem- 
brane attachment may be a regulatable event. Third, several 
laboratories have reported that palmitylated proteins, includ- 
ing unidentified proteins in the 18-24-kDa range, are incor- 
porated into the platelet cytoskeleton when platelets are 
activated (27). Finally, recent evidence suggests that some 
members of the ra.s family of proteins can be associated with 
intracellular membrane fractions, such as the Golgi apparatus 
and secretory vesicles (9, 10). The results obtained here dem- 
onstrate that raplB associates with the cell cytoskeleton 
during platelet activation and suggest a possible role for this 
cytoskeleton interaction in platelet function. 
EXPERIMENTAL PROCEDURES 
Reagents, buf’f’ers, and salts were obtained from Sigma. M90, a 
murine monoclonal antibody against ~21”‘” was produced as de- 
scribed previously (28). Human n-thrombin, kindly provided by Dr. 
Frank Church (Chapel Hill, NC), was prepared as detailed elsewhere 
(29) and was stored at -80 “C in 750 mM NaCl, 20 mM MES, 3 mM 
NaN:,, pH 7.5, until use. 
Platelets were prepared by differential centrifugation from fresh 
human blood as described previously (30) and suspended at a concen- 
tration of 10:’ cells/ml in titrated saline. Platelets were aggregated 
with stirring by the addition of CaC12 to a final concentration of 5 
mM followed 1 min later by l/100 dilution of stock thrombin to a 
final concentration of 1 unit/ml, A23187 to a final concentration of 
20 FM, or control buffer. After 5 min, cytoskeletons were extracted 
by a Triton X-100 lysis procedure (31). An equal volume of “lysis 
buffer” (145 mM NaCl, 0.1 mM MgCl?, 15 mM HEPES, 1.0 mM 
phenylmethylsulfonyl fluoride, 10 mM EGTA, 0.8 pg/ml leupeptin, 
1% (w/v) Triton X-100, pH 7.4) was added. After 5 min at 0 “C, the 
samples were centrifuged at 10,000 X g for 5 min. The resulting pellet 
was resuspended in “modified lysis buffer” (145 mM NaCl, 0.1 mM 
MgCl?, 15 mM HEPES, 0.5 mM phenylmethylsulfony1 fluoride, 5 mM 
EGTA, 0.4 pg/ml leupeptin, 1% (w/v) Triton X-100, pH 7.4) and 
centrifuged again as in the last step to obtain the cytoskeletal pellet. 
The 10,000 x g supernatant from the initial centrifugation step was 
centrifuged at 100,000 x i: for 1 h to obtain a 100,000 X g pellet, 
which contained the membrane skeleton (32), and a corresponding 
100,000 X fi supernatant that contained soluble cytosolic proteins and 
Triton X-100.solubilized membrane components. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was per- 
formed by the procedure of Laemmli (33) with reducing conditions 
on 12.5% polyacrylamide gels. Molecular mass standards were soy- 
bean trypsin inhibitor (21 kDa), carbonic anhydrase (29 kDa), oval- 
bumin (45 kDa), bovine serum albumin (67 kDa), phosphorylase b 
(97 kDa), and myosin (200 kDa). The amount of protein applied to 
each electrophoretic lane depicting intact platelets, 10,000 X g pellets, 
and 100,000 X g pellets was that obtained from 10” platelets, while 
the supernatant phases were from 2.5 x 10’ cells/lane. For Western 
blot analysis with the monoclonal antibody M90, proteins were elec- 
trotransferred to nitrocellulose and then immunodetected with a 
variation of the procedure of Towbin et al. (34) that used an alkaline 
phosphatase-conjugated second antibody system as detailed elsewhere 
(21). 
RESULTS 
To determine if raplB was a component of the activation- 
dependent cytoskeleton, resting platelets and platelets acti- 
vated by the addition of 1 unit/ml cu-thrombin were lysed in 
“lysis buffer” and then fractionated by differential centrifu- 
gation to recover a 10,000 x g pellet containing the activation- 
dependent cytoskeleton, a 100,000 X g pellet containing the 
membrane skeleton, and a 100,000 x g supernatant containing 
solubilized membrane components and cytosolic proteins (31, 
32). The results are presented in Fig. 1. In control platelets 
(panel A), raplB was present in the 100,000 X g supernatant 
(lanes 7 and 8) and was absent from the cytoskeleton (lanes 
3 and 4) and the membrane skeleton (lanes 5 and 6). As 
previously reported, the activation-dependent cytoskeleton is 
not fully assembled in resting platelets and contains mostly 
actin (31). Upon activation (panel B), there were marked 
changes in the composition of the cytoskeletal fraction. On 
Coomassie Blue-stained gels, protein bands with apparent 
molecular masses of 250, 200, 92, and 44 kDa, corresponding 
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FIG. 1. Cytoskeletal association of raplB. Washed human 
platelets were recalcified and aggregated by the addition of buffer 
(panel A) or 1 unit/ml human n-thrombin (panel R). After 5 min, 
cytoskeletal structures were isolated by Triton X-100 lysis and dif- 
ferential centrifugation. In each panel, lanes I, 3, 5, and 7 are Coo- 
massie Blue-stained gels and lanes 2, 4, 6, and 8 are Western blots 
developed with the murine monoclonal antibody, M90. Lanes I and 
2 are intact platelets (platelets), lanes 3 and 4 are the cytoskeletal 
fraction ( IOkpellet), lanes 5 and 6 are the membrane skeleton fraction 
(lOOk pellet), and lanes 7 and 8 are solubilized platelet proteins (lOOk 
super). The arrow and dashed lines refer to the position of raplB. 
Molecular mass standards are shown on the left in each panel. This 
result is representative of four experiments. 
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to the known cytoskeletal components actin-binding protein, 
myosin, cu-actinin, and actin, respectively, were observed in 
the cytoskeletal fraction (lane 3). Protein bands were also 
seen at 55-60 kDa, corresponding to the (Y, 6, and y chains of 
fibrinogen, and at 22 kDa. On Western blots, raplB was found 
entirely in the cytoskeletal fraction (lone 4) and had the same 
electrophoretic mobility as the 22-kDa band seen in Coo- 
massie-stained lanes. Fractions containing the membrane 
skeleton (panel B lanes 5 and 6) or the supernatant (lanes 7 
and 8) did not contain detectable raplB by either Western 
blot with M90 or by protein stain. When platelets were 
activated with the calcium ionophore A23187, results similar 
to those depicted in Fig. 1 were obtained (data not shown). 
The function of raplB and other low molecular weight G- 
proteins in platelets remains unclear. Our demonstration that 
raplB incorporates into the cytoskeleton during cell activa- 
tion suggests that it functions less in initial signal transduc- 
tion and more in subsequent events. Indeed, if the proposed 
roles of Sec4 and YPTl in yeast (9, 10) can be extended to 
other systems, one might speculate that raplB acts as a 
targeting mechanism in the cytoskeleton, perhaps mediating 
protein-protein interactions or the interaction of the cyto- 
skeleton with another cellular component, such as secretory 
DISCUSSION 
We present evidence that raplB, a ras-like protein that 
both binds GTP and is a substrate for CAMP-dependent 
protein kinase, is incorporated into the cytoskeleton of human 
platelets during cell activation. These data provide direct 
evidence for a possible role of raplB in cytoskeletal assembly 
and amplify previous studies in other cells indirectly impli- 
cating low molecular weight G proteins in cytoskeletal func- 
tion (35, 36). 
The cellular skeleton of platelets contains several structural 
components (31, 32, 37). The membrane skeleton consists of 
short actin filaments cross-linked by actin-binding protein 
and is linked to the glycoprotein Ib-IX complex in the plasma 
membrane. It provides the platelet with its shape and plays 
an important role in determining the organization and func- 
tion of the GPIb-IX complex in the plasma membrane. This 
structure is present in resting platelets but is disrupted follow- 
ing platelet activation, at least in part due to the cleavage of 
actin-binding protein by the calcium-activated protease (38, 
39), calpain, resulting in changes in platelet shape and in- 
creased mobility of membrane proteins. The cytoplasmic skel- 
eton or cytoskeleton from resting platelets consists primarily 
of a mesh of actin filaments. When platelets are activated, 
actin, myosin, and actin-binding protein are incorporated into 
the cytoskeleton. Our results indicate that raplB is a com- 
ponent of the activation-dependent cytoskeleton, but not of 
the membrane skeleton, even though raplB is membrane- 
bound in resting platelets. Furthermore, in contrast to other 
cytoskeletal proteins such as actin-binding protein and actin, 
which are only partly incorporated into the cytoskeleton, all 
of the immunodetectable raplB becomes incorporated into 
the cytoskeleton during activation. This quantitative incor- 
poration of raplB is distinct and suggests that the cytoskeletal 
interaction is an important one. 
In addition to raplB, two other cytoskeletal proteins have 
been identified as CAMP-dependent protein kinase substrates: 
the /3 subunit of GPIb (40), which is present in the membrane 
skeleton, and actin-binding protein (41). Cyclic AMP-depend- 
ent phosphorylation of GPIbfi in intact platelets did not 
inhibit agonist-stimulated aggregation, secretion, or phos- 
phorylation of myosin light chain or ~47. However, agonist- 
stimulated actin polymerization was inhibited suggesting that 
phosphorylation of GPBIbp influenced cytoskeletal assembly 
(25). In preliminary studies, we have tried to examine the 
effect of phosphorylation on raplB incorporation into the 
cytoskeleton, but treatment with agents that increased CAMP 
levels inhibited cytoskeletal assembly.3 The identification of 
three proteins involved in the CAMP pathway as components 
of the platelet cytoskeleton is remarkable and suggests that 
at least one of the inhibitory mechanisms of CAMP is through 
an effect on the cytoskeleton. 
a T. H. Fischer and G. C. White II, unpublished data. 
granules. 
In summary, the membrane interactions of raplB in plate- 
lets appear to be complex but may ultimately yield important 
clues to the function of the low molecular G proteins. In 
resting platelets, raplB is associated with the cell membrane, 
probably the plasma membrane, and probably through a po- 
lyisoprenyl group. Whether or not this involves changes in 
the posttranslational modification of raplB remains to be 
determined. When the cell is inhibited by CAMP, raplB is 
translocated from the membrane to a cytosolic location (19). 
When the cell is activated, raplB becomes incorporated into 
the cytoskeleton. This bidirectional translocation may be 
essential for normal cell function. 
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